By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


RedHill Biopharma Ltd. 

21 Ha’arba’a Street

Tel-Aviv    64739  Israel
Phone: 972-0-3-541-3131 Fax: 972-0-3-541-3144



Company News
RedHill Biopharma (RDHL) Announces YELIVA (ABC294640) Poster Presentation At The 2016 EORTC-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium 11/21/2016 11:20:10 AM
RedHill Biopharma (RDHL) Reports Positive FDA Type B Meeting on RHB-105 For H. pylori Infection Ahead Of Confirmatory Phase III Study 11/10/2016 8:56:55 AM
RedHill Biopharma (RDHL) Provides Update On Ongoing Phase III And Phase II Studies With BEKINDA And Expected Timing Of Top-Line Results 11/3/2016 10:22:28 AM
RedHill Biopharma (RDHL) Announces Withdrawal Of Public Offering Of Its American Depositary Shares 11/3/2016 9:52:09 AM
RedHill Biopharma (RDHL) Announces Proposed Public Offering Of Its American Depository Shares 11/2/2016 9:49:30 AM
RedHill Biopharma (RDHL) Announces Allowance Of A Patent In Japan Supporting RHB-104 For Multiple Sclerosis 10/18/2016 11:54:29 AM
RedHill Biopharma (RDHL) To Host Webcast Today At 8:30 Am EDT Following Announcement Of Progress Update On RHB-104 Phase III Crohn’s Disease Program 10/6/2016 10:50:21 AM
RedHill Biopharma (RDHL) Provides Progress Update On RHB-104 Phase III Crohn’s Disease Program And Introduces Option For Early Stop For Success In Q2/2017 10/6/2016 10:16:18 AM
RedHill Biopharma (RDHL) Announces Initiation Of Phase II Study With YELIVA In Hepatocellular Carcinoma At Medical University of South Carolina 10/5/2016 9:20:24 AM
RedHill Biopharma (RDHL) And IntelGenx Corp. Announce RIZAPORT Commercialization Term Sheet With Pharmatronic Co. For Korea 9/21/2016 8:40:08 AM